{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:34:21Z","timestamp":1790728461141,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W005611\/1"],"award-info":[{"award-number":["MR\/W005611\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X006751\/1"],"award-info":[{"award-number":["MR\/X006751\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y004205\/1"],"award-info":[{"award-number":["MR\/Y004205\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2041"],"award-info":[{"award-number":["CC2041"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2230"],"award-info":[{"award-number":["CC2230"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2166"],"award-info":[{"award-number":["CC2166"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC0102"],"award-info":[{"award-number":["CC0102"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC1114"],"award-info":[{"award-number":["CC1114"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2060"],"award-info":[{"award-number":["CC2060"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC1283"],"award-info":[{"award-number":["CC1283"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010438","name":"The Francis Crick Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018835","name":"NIHR Sheffield Clinical Research Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126960","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:41:08Z","timestamp":1741333268000},"page":"126960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics"],"prefix":"10.1016","volume":"54","author":[{"given":"Giulia","family":"Dowgier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Shawe-Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Stevenson-Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bazire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Libri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Gamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.V.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2025.126960_bb0005","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2025.126960_bb0015","series-title":"WHO\/BS\/2022.2427: Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern","year":"2022"},{"key":"10.1016\/j.vaccine.2025.126960_bb0020","series-title":"WHO\/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody","year":"2020"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126960_bb0025","first-page":"420","article-title":"Antibody correlates of protection against Delta infection after vaccination: a nested case-control within the UK-based SIREN study","volume":"87","author":"Atti","year":"2023","journal-title":"J Inf Secur"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126960_bb0030","first-page":"545","article-title":"Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study","volume":"85","author":"Atti","year":"2022","journal-title":"J Inf Secur"},{"issue":"10432","key":"10.1016\/j.vaccine.2025.126960_bb0035","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(24)00316-7","article-title":"Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign","volume":"403","author":"Shawe-Taylor","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126960_bb0040","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1473-3099(23)00705-3","article-title":"SARS-CoV-2 mucosal neutralising immunity after vaccination","volume":"24","author":"Carr","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126960_bb0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(23)00289-X","article-title":"Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous omicron infection","volume":"23","author":"Carr","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"10326","key":"10.1016\/j.vaccine.2025.126960_bb0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0140-6736(22)00092-7","article-title":"Three-dose vaccination elicits neutralising antibodies against omicron","volume":"399","author":"Wu","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126960_bb0055","article-title":"Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer","volume":"3","author":"Fendler","year":"2022","journal-title":"Cell Rep Med"},{"issue":"10328","key":"10.1016\/j.vaccine.2025.126960_bb0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(22)00147-7","article-title":"Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer","volume":"399","author":"Fendler","year":"2022","journal-title":"Lancet"},{"issue":"10327","key":"10.1016\/j.vaccine.2025.126960_bb0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(22)00104-0","article-title":"Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients","volume":"399","author":"Carr","year":"2022","journal-title":"Lancet"},{"issue":"10292","key":"10.1016\/j.vaccine.2025.126960_bb0070","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet"},{"issue":"10296","key":"10.1016\/j.vaccine.2025.126960_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(21)01462-8","article-title":"AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC","volume":"398","author":"Wall","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126960_bb0080","first-page":"1305","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Can"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126960_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294897","article-title":"COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants omicron BA.1, BA.2, BA.4\/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history","volume":"19","author":"Townsley","year":"2024","journal-title":"PLoS One"},{"issue":"655","key":"10.1016\/j.vaccine.2025.126960_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3715","article-title":"SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies","volume":"14","author":"Ng","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.126960_bb0095","first-page":"10","article-title":"Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains","author":"Faulkner","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2025.126960_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126960_bb0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"49","key":"10.1016\/j.vaccine.2025.126960_bb0110","doi-asserted-by":"crossref","first-page":"17264","DOI":"10.1073\/pnas.0407639101","article-title":"The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter","volume":"101","author":"Andrejeva","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126960_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02859-23","article-title":"Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage","volume":"12","author":"Minami","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126960_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02186-21","article-title":"Rapid SARS-CoV-2 adaptation to available cellular proteases","volume":"96","author":"Chaudhry","year":"2022","journal-title":"J Virol"},{"issue":"7849","key":"10.1016\/j.vaccine.2025.126960_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","article-title":"Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis","volume":"591","author":"Johnson","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126960_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41541-021-00346-z","article-title":"A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells","volume":"6","author":"Funnell","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126960_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/v13122434","article-title":"Propagation of SARS-CoV-2 in Calu-3 cells to eliminate mutations in the Furin cleavage site of spike","volume":"13","author":"Baczenas","year":"2021","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126960_bb0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14712598.2024.2388186","article-title":"Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19","volume":"24","author":"Casadevall","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126960_bb0145","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ccell.2023.04.005","article-title":"Sotrovimab restores neutralization against current omicron subvariants in patients with blood cancer","volume":"41","author":"Wu","year":"2023","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.vaccine.2025.126960_bb0155","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126960_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/11786302241228958","article-title":"JN.1: the present public health concern pertains to the emergence of a novel variant of COVID-19","volume":"18","author":"Khan","year":"2024","journal-title":"Environ Health Insights"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126960_bb0165","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41564-021-00908-w","article-title":"The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets","volume":"6","author":"Peacock","year":"2021","journal-title":"Nat Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126960_bb0170","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol Cell"},{"issue":"21","key":"10.1016\/j.vaccine.2025.126960_bb0175","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01357-21","article-title":"Natural and recombinant SARS-CoV-2 isolates rapidly evolve in vitro to higher infectivity through more efficient binding to Heparan sulfate and reduced S1\/S2 cleavage","volume":"95","author":"Shiliaev","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.126960_bb0180","series-title":"Statement on the antigen composition of COVID-19 vaccines","author":"WHO","year":"2024"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126960_bb0185","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1038\/s41467-023-38435-3","article-title":"Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two omicron subvariants","volume":"14","author":"Tamura","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126960_bb0190","doi-asserted-by":"crossref","first-page":"8728","DOI":"10.1038\/s41467-024-53033-7","article-title":"Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86\/JN.1 and EG.5.1\/HK.3","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126960_bb0195","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","article-title":"Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure","volume":"24","author":"Yang","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126960_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"The Lancet Regional Health - Europe"},{"key":"10.1016\/j.vaccine.2025.126960_bb0205","article-title":"What is the future for covid drugs and treatments?","volume":"381","author":"Looi","year":"2023","journal-title":"BMJ"},{"issue":"7815","key":"10.1016\/j.vaccine.2025.126960_bb0210","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126960_bb0215","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct early serological signatures track with SARS-CoV-2 survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126960_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253487","article-title":"The fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody","volume":"16","author":"Chan","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126960_bb0225","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","article-title":"Compromised humoral functional evolution tracks with SARS-CoV-2 mortality","volume":"183","author":"Zohar","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126960_bb0230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"642","key":"10.1016\/j.vaccine.2025.126960_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn9243","article-title":"Omicron variant spike-specific antibody binding and fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines","volume":"14","author":"Bartsch","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:42:33Z","timestamp":1762278153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25002579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"alternative-id":["S0264410X25002579"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126960","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126960"}}